News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase III (World)
SALVAT Announces Positive Top-Line Results From Two Phase 3 Studies Of Its Novel Otic Antibiotic/Steroid Combination Solution In The Treatment Of AOMT With Tympanostomy Tubes 9/29/2014
Helsinn Group Release: Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Shows Significant Increase In Lean Body Mass, Body Weight And Improved Symptoms 9/29/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014
Novartis AG (NVS) Reports Two Positive Phase 3 Trials For Arthritis Drug 9/26/2014
Bausch & Lomb Announces Successful Results From Phase 3 Study Of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% 9/26/2014
Roche (RHHBY)’s Avastin Prolongs Life In Breast Cancer Study 9/25/2014
NicOx SA (COX.PA) Gets Boost From Strong Prospects For Glaucoma Drug Vesneo 9/25/2014
Helsinn Announces That Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Will Be Presented At The 38th European Society For Medical Oncology (ESMO) Congress In 2014 9/25/2014
Alcobra (ADHD) Announces Completion Of All Patient Visits In Phase 3 Clinical Trial Of MDX In Adult ADHD 9/22/2014
TauRx Therapeutics Achieves Enrollment Target For Second Phase 3 Clinical Trial Of LMTX™ In Alzheimer's Disease 9/22/2014
BioTime (BTX) Announces Presentation Of Phase 3 Data At EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 9/19/2014
Novo Nordisk A/S (NVO)'s Diabetes Drug Ryzodeg Effective In Phase 3b Study 9/18/2014
Janssen-Cilag International NV (JNJ) Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adults 9/17/2014
CSL Behring Announces Last Patient Treated In Phase 3 Study Of Fibrinogen Concentrate To Control Bleeding During Aortic Aneurysm Surgery 9/16/2014
Roche (RHHBY) Starts Pivotal Late-Stage Trial For Eye Drug Lampalizumab 9/15/2014
Evotec AG (EVTG.F) Announces Update On DiaPep277® 9/8/2014
Successful Completion Of Phase 3 Program For Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Two More Phase Iii Studies Support The Benefits Of Reslizumab Treatment In Asthma Patients With Eosinophilia 9/8/2014
Boehringer Ingelheim Corporation Release: TONADO™ - Further Lung Function And Quality Of Life Benefits With Tiotropium + Olodaterol Respimat® FDC* In COPD 9/8/2014
Novartis AG (NVS)'s New Heart Drug Cuts Cardiovascular Death Risk By 20 Percent; "Most Exciting Ever" Med Points To Huge Sales 9/4/2014
RedHill Biopharma Ltd. (RDHL) Initiates Phase 3 Study Of RHB-102 For Gastroenteritis 9/3/2014
Final Landmark Trial Confirms Efficacy Of Sanofi (France) (SAN.PA)'s Dengue Vaccine 9/3/2014
Early Phase 3 Data Suggest Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
Macrocure (MCUR) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Curexcell In Diabetic Foot Ulcers 9/2/2014
Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Delivers Clinically And Statistically Significant Reduction In Asthma Exacerbations In Two Pivotal Phase 3 Studies 9/2/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On Expansion Of Ongoing RHB-105 Phase 3 Study, Targeting Broadened H. Pylori Indication Authorized By FDA 8/27/2014
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014
AstraZeneca PLC (AZN) Starts Late-Stage Asthma Drug Trial 8/14/2014
Mologen AG (MOLGF.PK): Preparation And Launch Of New Studies Characterized The First Half-Year 2014 8/13/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results 8/13/2014
Cortendo AB: First Patient Enrolled Into Normocort Phase 3 SONICS Trial Following A Successful EU Investigator Meeting 8/12/2014
Novartis AG (NVS) To Tout Heart Failure Data At European Society of Cardiology Congress 2014 8/12/2014
Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 8/11/2014
New Data Shows High Efficacy For Can-Fite BioPharma (CFBI)'s CF101 In Rheumatoid Arthritis And Psoriasis Patients 8/6/2014
Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696 8/5/2014
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK)'s Ofatumumab Meets Primary Endpoint In Late-Stage Study 8/1/2014
Alkermes plc (ALKS) Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 7/30/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 7/18/2014
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease 7/17/2014
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014
Alcobra (ADHD) Completes Patient Recruitment In Phase 3 Clinical Trial Of MDX In Adult ADHD 7/14/2014
FDA Green Lights Starpharma Holdings Ltd's VivaGel Trial Design 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria 7/8/2014
Endo International plc (ENDP), BioDelivery Sciences International (BDSI) Painkiller BEMA® Buprenorphine Effective In Phase 3 Study 7/7/2014
Bayer Inc. Release: Nexavar® (sorafenib tablets) Now Approved In Canada For The Treatment Of Differentiated Thyroid Cancer 7/7/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO) Leukemia Drug Ofatumumab Fails To Meet Main Trial Goal 7/2/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014
H. Lundbeck A/S (LUN.CO)'s Late Stage Trials For Stroke Failed To Meet Primary Endpoint 6/27/2014
Eisai Inc. (ESALF.PK) & Helsinn Group To Present New CINV Research At 2014 International Symposium On Supportive Care In Cancer 6/26/2014
FDA Requests More Data For Basilea Pharmaceutica (BSLN.SW)'s Pneumonia Drug Ceftobiprole; Stock Drops -8.15% At Market Close (June 25, 2014) 6/25/2014
Orexo AB (ORXOF) Release: Top-Line Data From A Phase 3 Clinical Trial Demonstrates That Zubsolv® Is As Effective As Suboxone® Film In The Treatment Of Opioid Dependence 6/25/2014
Agreement On Phase 3 Trial Protocol Of OSE Pharma's OSE-2101 From The FDA And European Medicines Agency 6/24/2014
Positive New Phase 3a Data On Novo Nordisk A/S (NVO)'s Liraglutide 6/23/2014
Orexo AB (ORXOF) Release: Positive Top-Line Results From Two Phase 3 Clinical Trials That Assessed Zubsolv® For Induction Of Buprenorphine Maintenance Therapy 6/23/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014
Boehringer Ingelheim (Canada) Ltd. Release: Study Findings Show Tiotropium Respimat®* Well-Tolerated And Effective In Japanese Patients With Symptomatic Asthma 6/19/2014
Successful Phase 3 Results For Alkermes plc (ALKS)'s Schizophrenia Drug Aripiprazole Lauroxil 6/19/2014
Actelion Ltd. (ALIOF.PK) Soars As Heart-Lung Drug Selexipag Meets Main Goal In Late-Stage Study 6/18/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Novo Nordisk A/S (NVO)'s Big-Selling Diabetes Drug Victoza Appears Effective For Weight Loss 6/16/2014
Sanofi (France) (SAN.PA) Toujeo Shows Great Promise As Lantus Successor 6/16/2014
Novo Nordisk A/S (NVO) Combination Diabetes Drug IDegLira Effective After 1 Year Study 6/16/2014
Eli Lilly and Company (LLY) Release: Type 2 Diabetes: Jardiance® (Empagliflozin) As An Add-On Therapy Significantly Reduced Blood Glucose And Body Weight In Two Newly Presented Phase 3 Trials 6/16/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Tout Positive Phase 3 Data For Rheumatoid Drug Sarilumab 6/13/2014
All Eyes Are On AstraZeneca PLC (AZN) As Its Diabetes Drugs Go Under The Spotlight At Major Scientific Meeting 6/12/2014
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference 6/12/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Put Out Positive Update On Two Phase 3 Ellipta COPD Studies 6/11/2014
EULAR: Romosozumab Significantly Increases Bone Mineral Density And Bone Content Compared With Teriparatide 6/11/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Northwest Biotherapeutics (NWBO) Release: DCVAX®-L Phase 3 Trial Initiated In Germany 6/10/2014
ALK-Abello A/S Presents Phase 3 Data On House Dust Mite SLIT-Tablet At EAACI Annual Congress In Copenhagen 6/9/2014
GlaxoSmithKline (GSK) Launches Huge Phase 3 Study For Heart Drug Losmapimod 6/9/2014
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 6/6/2014
RedHill Biopharma Ltd. (RDHL) Announces New RHB-104 Patent In Japan And Provides Update On Phase 3 Crohn's Program 6/5/2014
Jiangsu Hengrui Medicine Co. Ltd. Reports Positive Phase 3 Data For Cancer Drug 6/4/2014
Dainippon Sumitomo Pharma Co., Ltd. Halts Key Phase 3 Global Colorectal Carcinoma Monotherapy Trial 5/28/2014
RedHill Biopharma Ltd. (RDHL) Announces FDA Clearance For Phase 3 Study With RHB-102 Planned To Commence In Q3/2014 5/22/2014
Santhera Pharmaceuticals AG (SANN.SW) Reports Positive Outcome For Catena®/Raxone® In Phase 3 DMD Trial Supported By Additional Respiratory Function Data 5/22/2014
SOTIO Initiates VIABLE, A Global Phase 3 Clinical Trial For Prostate Cancer Immunotherapy Treatment With DCVAC/PCa 5/22/2014
Boehringer Ingelheim Corporation Stakes Claim To Combination COPD Market As Phase 3 Data For Tiotropium Is Positive 5/22/2014
RedHill Biopharma Ltd. (RDHL) And IntelGenx Corp. Report Positive RHB-103 Bioavailability Study Results In Support Of Planned European Marketing Application In Q3/2014 5/21/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO)' Arzerra Fails Phase 3 Lymphoma Trial 5/21/2014
Kamada Ltd. (KMDA) Crashes After Key Trial Failure 5/19/2014
In The Battle Of Idiopathic Pulmonary Fibrosis Drugs, Boehringer Ingelheim Corporation's Nintedanib Wows In Phase 3 Trial 5/19/2014
Basilea Pharmaceutica (BSLN.SW) Reports Additional Data On Positive Isavuconazole Phase 3 SECURE Study At ECCMID 5/14/2014
Mologen AG (MOLGF.PK): Development Of Main Product Candidate Pushed Forward Swiftly In First Quarter 5/14/2014
Santhera Pharmaceuticals AG (SANN.SW) Announces Successful Outcome Of Phase 3 Study With Catena®/Raxone® In Duchenne Muscular Dystrophy 5/14/2014
Gene Signal Announces Positive Data From Phase 3 Trial of Aganirsen Eye Drops For Corneal Neovascularisation Due To Inflammation, A Rare Eye Disease With European Orphan Drug Designation 5/14/2014
GlaxoSmithKline (GSK)'s Once Promising Heart Drug Strikes Out Again 5/14/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Psoriasis Drug Brodalumab Meets Goals In Phase 3 Study 5/14/2014
Taiho Oncology's TAS-102 Meets Primary Endpoint Of Improving Overall Survival In Global Phase 3 RECOURSE Trial In Refractory Metastatic Colorectal Cancer 5/12/2014
AstraZeneca PLC (AZN) Jumps Start Late-Stage Study Of Key New Cancer Drug 5/9/2014
Immune Pharmaceuticals, Inc. Announces Phase 3 Development And Commercialization Strategy For AMIKET 5/5/2014
Endocyte, Inc. (ECYT), Merck & Co., Inc. (MRK) Halt Study Of Ovarian Cancer Drug Vintafolide; Endocyte Stock Plunges -61.91% At Market Close (May 2, 2014) 5/2/2014
Teva Pharmaceutical Industries Limited (TEVA) Reports Positive Results From Pivotal Phase 3 Study To Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) For Moderate To Severe Chronic Low Back Pain 4/30/2014
RedHill Biopharma Ltd. (RDHL) Reports Successful RHB-102 Bioavailability Clinical Trial And Planned Submission Of European Marketing Application In Q3/2014 4/30/2014
OncoGenex Pharmaceuticals Inc. (OGXI)'s Long Awaited Cancer Drug Ends With A Phase 3 Stumble; Stock Down -60.31% At Market Close (April 28, 2014) 4/30/2014
Cell Therapeutics, Inc. (CTIC) PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 4/29/2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA In Cancer Pain 4/28/2014
IntelGenx Corp. And RedHill Biopharma Ltd. (RDHL) Announce Commencement Of A Bioavailability Study With Anti-Migraine Versafilm™ Product To Support European Marketing Application Planned For Q3/2014 4/28/2014
Merck & Co., Inc. (MRK) Announces Positive Outcome Of 3b Study For Kuvan 4/24/2014
Boehringer Ingelheim Corporation Rethinks Hepatitis Business, Braces For A Rough 2014 4/17/2014
AbbVie (ABBV)'s Experimental Hepatitis C Regimen Associated With High Cure Rates In Late-Stage Studies 4/15/2014
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase III Clinical Trial With Livatag® In Primary Liver Cancer 4/14/2014
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase 3 Clinical Trial With Livatag® In Primary Liver Cancer 4/14/2014
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Blood Disorder Drug Succeeds In Phase 3 Trial 4/10/2014
Alkermes plc (ALKS) Pulls Off Phase 3 Win for Long-Lasting Schizophrenia Drug 4/9/2014
GlaxoSmithKline (GSK) Halts Late-Stage Lung Cancer Vaccine Trial 4/3/2014
Medivir AB (MVRBF) Release: Two Phase 3 Trials Evaluating Once-Daily Simeprevir And Sofosbuvir In Hepatitis C Infected Patients Have Been Initiated 4/2/2014
Novartis AG (NVS) Closes Heart Drug Study Early After Strong Results 4/1/2014
Novartis AG (NVS)'s Rare Lung Cancer Drug Ceritinib Shows Positive Response In Study 3/27/2014
Swedish Orphan Biovitrum Release: Kiobrina Pivotal Phase 3 Study Did Not Meet Primary Endpoint 3/26/2014
CogState Ltd (CGS.AX)'s Technology Chosen For Major Phase 3 Trial Of Alzheimer's Disease Drug 3/25/2014
Novo Nordisk A/S (NVO) Reports Positive Results From First Phase 3 Trial With N8-GP, A Long-Acting Factor VIII For Treatment Of Haemophilia A 3/19/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 3 Clinical Trial For MDX In Adult ADHD 3/18/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Touts Positive Results From Three COPD Phase 3 Studies 3/17/2014
Medivir AB (MVRBF) Release: New Phase 3 Data From Once-Daily Simeprevir Presented At The Conference Of The Asian Pacific Association For The Study Of The Liver (APASL) 3/17/2014
GlaxoSmithKline (GSK) Touts Positive Asthma Drug Results From Two Phase 3 Studies 3/14/2014
CrystalGenomics Announces Positive Results Of Phase 3 Trial Of Polmacoxib (CG100649) In Patients With Osteoarthritis 3/13/2014
Novartis AG (NVS) Drug Jakavi® Gets Tagged As A Potential Blockbuster After Positive Late-Stage Study 3/10/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On RHB-102 Development And Intellectual Property 3/7/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 3/5/2014
LFB S.A. Initiates Global Phase 3 Clinical Trial Of New Coagulation Factor Viia (Recombinant) In Patients With Hemophilia A And B 3/3/2014
Actelion Ltd. (ALIOF.PK)'s Diarrhea Treatment Gets Fast-Track From The FDA 3/3/2014
Sinovac Biotech Ltd. (SVA)'s EV71 Vaccine Phase III Clinical Trial Results Published In The New England Journal of Medicine 2/27/2014
Shire plc Release:” New Phase 3 Data For Guanfacine Extended Release (GXR) To Be Presented At European Congress Of Psychiatry 2/27/2014
AB Science (AB.PA): Initiation Of A New Phase 3 Study With Masitinib In Prostate Cancer, Following Encouraging Survival Results Obtained In A Phase 2 Study 2/21/2014
Auris Medical AG Announces Enrollment Of First Patient In European Phase 3 Study Of AM-101 In Treatment Of Acute Peripheral Tinnitus 2/21/2014
AB Science (AB.PA): Initiation Of A New Phase 3 Study With Masitinib In Prostate Cancer, Following Encouraging Survival Results Obtained In A Phase 2 Study 2/20/2014
Active Biotech AB (BTPC) Release: Change In The Clinical Development Program For Laquinimod 2/19/2014
AstraZeneca PLC (AZN) Chases Demon Disease Cure, Potential To Be A Blockbuster Drug 2/17/2014
GlaxoSmithKline (GSK) Finally Starts Much-Anticipated Phase 3 Study For Rare Disease 2/17/2014
Merck & Co., Inc. (MRK) Joins Race To Copy Sanofi (France) (SAN.PA)'s Lantus 2/12/2014
Ipsen (IPN.PA) Says Phase 3 Prostate Cancer Drug Study Results Are Positive 2/7/2014
Shire plc Scraps Vyvanse® For Depression After Failed Phase 3 Trials 2/7/2014
Zealand Pharma  (ZEAL.CO) Informs That Sanofi (France) (SAN.PA) Has Announced Initiation Of The Lixilan Phase 3 Clinical Program For The Fixed-Ratio Combination Of Lantus® And Lyxumia® 2/6/2014
GlaxoSmithKline (GSK) Talks Up Its Pipeline 2/6/2014
Ipsen (IPN.PA) Announces Clinical Results Of Dysport® Next Generation (DNG) And Its Intent To File The First Ready-To-Use Liquid Toxin A In Europe And ROW1 2/5/2014
Medivation, Inc. (MDVN) Prevails Again As Prostate Cancer Drug Impresses In Pre-Chemo Study 1/30/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) To Present New Data On Brexpiprazole In Major Depression (MDD) At European Congress Of Psychiatry (EPA) 1/24/2014
Roche (RHHBY)'s Schizophrenia Drug, Bitopertin, Misses Goal In Two Late-Stage Trials 1/22/2014
ProSensa Holding N.V. (RNA) Reports Initial Findings From The Further Clinical Data Analyses Of Drisapersen For The Treatment Of Duchenne Muscular Dystrophy 1/16/2014
Zealand Pharma  (ZEAL.CO) Announces Advance By Sanofi (France) (SAN.PA) Of Lixilan, The Single Injection Lyxumia®/Lantus® Combination Product, Towards Phase 3 Development And A Related Milestone Payment 1/15/2014
Shield Therapeutics' ST10 Delivers Robust Results Meeting Both Primary And Secondary Endpoints In The Pivotal AEGIS Phase 3 Program For The Treatment Of Iron Deficiency Anemia In Inflammatory Bowel Disease 1/7/2014
ADImmune Corporation Plans To Sell Its Flu Vaccine In China This Year 1/7/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On Pk Program In Support Of Ongoing Rhb-104 Phase 3 Crohn's Study 1/6/2014
TauRx Therapeutics Expands Alzheimer's Clinical Trials In The United States 1/6/2014
Takeda Pharmaceutical Co. Ltd. (TKPYY) Dealt A Huge Blow As Development Of Diabetes Drug Is Terminated 1/2/2014
OphthaliX Inc.'s Dry Eye Drug CF101 Fails To Meet Goals In Phase 3 Study 12/31/2013
Veloxis Pharmaceuticals A/S (VELO) Envarsus® Granted Orphan Drug Status By FDA For Kidney Transplant Rejection Prophylaxis 12/27/2013
RedHill Biopharma Ltd. (RDHL) Reports Positive PK Results In Support Of Ongoing RHB-105 Phase 3 H. Pylori Study 12/23/2013
ProSensa Holding N.V. (RNA) Comments On Drisapersen Program Update 12/20/2013
Onconova Therapeutics Inc. (ONTX) Tanks As Study Of Lead Pancreatic Drug Fails Phase 3 Trial; Stock Down -18.68% At Market Close (Dec. 18, 2013) 12/19/2013
Andromeda Biotech Announces First Patient Dosed In Extension Study To Its Phase 3 Clinical Trial DIA-AID 2 In Patients With Type 1 Diabetes 12/18/2013
Ipsen (IPN.PA) Announces Positive Initial Results From The International Double-Blind Clinical Phase III Study of Dysport® In The Treatment Of Adults Suffering From Upper Limb Spasticity 12/17/2013
RedHill Biopharma Ltd. (RDHL) Announces First Patients Dosed In Phase 3 Study Of RHB-105 For H. Pylori Infection 12/17/2013
FINOX Biotech Announces First Patients Enrolled In Pivotal US Phase III (FIN3002) Study For Rfsh 12/17/2013
AstraZeneca PLC (AZN) Announces Top-Line Results From Phase 3 Monotherapy Study Of Lesinurad In Gout Patients 12/16/2013
Hepatitis C: Phase 3 Data Show Boehringer Ingelheim Corporation's Faldaprevir* Is Effective Even In Patients With Common Drug-Resistant Viral Variant 12/16/2013
Kamada Ltd. (KMDA.TA) Announces Completion Of Pivotal Phase 2/3 Clinical Trial In Europe And Canada Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency 12/11/2013
Novartis AG (NVS) Bone Marrow Cancer Drug Wows In Late-Stage Study 12/9/2013
Phase 3 Data Show Daiichi Sankyo, Inc. (4568.t)'s Once-Daily Edoxaban Lowered Incidence Of VTE Recurrence And Clinically Relevant Bleeding Compared To Warfarin In A Large Subgroup Of Patients With Cancer 12/9/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) And Swedish Orphan Biovitrum Release: New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ And ELOCTATE™ Across Multiple Hemophilia Populations 12/9/2013
GlaxoSmithKline (GSK), Theravance, Inc. (THRX)'s Asthma Drug Improved Lung Function In Phase 3 Study 12/9/2013
Shire plc's New Eye Drug, Lifitegrast, Disappoints In Pivotal Trial 12/6/2013
BioAlliance Pharma Release: Approval To Start Relive (Livatag®) Phase III Clinical Trial In Primary Liver Cancer In The US And Germany 12/4/2013
New Phase 3 Data Backs Promise Of Sanofi (France) (SAN.PA)'s Long-Acting Insulin 12/4/2013
Novo Nordisk A/S (NVO)'s Ryzodeg® Offers Improved Glycemic Control With Significantly Lower Rates Of Hypoglycaemia Compared To Biphasic Insulin Aspart 30 In Adults With Type 2 Diabetes 12/3/2013
Swedish Orphan Biovitrum's Partner Biogen Idec, Inc. (Massachusetts) (BIIB) To Present Phase 3 Data On Prolonged Half-Life Of Hemophilia Candidates In Young Children At Annual American Society of Hematology Meeting 12/3/2013
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Qualified Infectious Disease Product (QIDP) Designation From U.S. FDA For The Treatment Of Invasive Aspergillosis 12/3/2013
AB Science (AB.PA) Announces Initiation Of A New Phase 3 Study In Oncology With Masitinib In Patients With Metastatic Colorectal Cancer 12/3/2013
RedHill Biopharma Ltd. (RDHL) Announces First Patient Dosed In Phase 3 Study Of RHB-104 For Crohn's Disease 11/25/2013
Novartis AG (NVS) Chases Pfizer Inc. (PFE) In Hot New Breast Cancer Drug Area 11/25/2013
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Arthritis Drug Meets Goals In Phase 3 Study 11/22/2013
Basilea Pharmaceutica (BSLN.SW) Reports Isavuconazole Orphan Drug Designation For Treatment Of Zygomycosis By FDA 11/18/2013
GW Pharmaceuticals Provides Update On Orphan Program In Childhood Epilepsy For Epidiolex® 11/15/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) and Swedish Orphan Biovitrum Release: Leading Hematology Journal Publishes Pivotal Eloctate Tm Data That Demonstrated Efficacy And Safety Of Investigational Long-Lasting Therapy For Hemophilia A 11/13/2013
GlaxoSmithKline (GSK) Heart Drug Misses Goal In Major Study 11/13/2013
AB Science (AB.PA): Final Results Of Phase 3 Mastocytosis Study Expected By End Of 2014 11/12/2013
Clinuvel Successful In U.S. Phase III Trial Of SCENESSE® In Rare Skin Disorder 11/11/2013
AB Science (AB.PA): Masitinib Successfully Passes Futility Analysis in Pivotal Clinical Study in Mastocytosis 11/11/2013
ALK-Abello A/S's Partner In North America, Merck & Co. (Westpoint, PA) (MRK), Reports Phase III Data On Investigational Grass Sublingual Allergy Immunotherapy Tablet 11/11/2013
Pharming Group (PHGUF.PK) and Santarus Inc. (SNTS) Announce New Data From Open-Label Repeat Treatment Study With Rucomest 11/8/2013
Genentech (RHHBY)'s Gazyva Extends Leukemia Patients’ Survival 11/7/2013
ProSensa Holding N.V. (RNA) Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy 11/7/2013
Bone Therapeutics' Pivotal Phase III Osteonecrosis Trial With PREOB® hits a New Milestone 11/7/2013
Shire plc's ADHD Drug Succeeds in Phase 3 Trial to Treat Binge Eating 11/5/2013
Auris Medical AG Reaches Special Protocol Assessment Agreement With FDA for Pivotal Phase III Clinical Trial With AM-101 in Treatment of Acute Peripheral Tinnitus 11/4/2013
Medivir AB (MVRBF) Announces That New Simeprevir Data Will be Presented at the American Association for Study of Liver Diseases Meeting 11/4/2013
FDA Clears Commencement of Phase 3 Chronic Heart Failure Trial Using Mesoblast Limited (MSB.AX)'s Proprietary Cells 10/31/2013
RedHill Biopharma Ltd. (RDHL) Initiates Phase III Study of RHB-105 for H. pylori Infection 10/30/2013
Boehringer Ingelheim Corporation Release: New Data show Striverdi® (olodaterol)* Respimat® Improves Exercise Tolerance in Patients With Moderate to Very Severe COPD1 10/29/2013
Roche (RHHBY)'s Investigational Roactemra Subcutaneous Formulation Shows Comparable Long-Term Efficacy and Tolerability to the Intravenous Formulation in Rheumatoid Arthritis 10/28/2013
BioAlliance Pharma Announces Third Positive DSMB Recommendation to Continue Its Phase III Clinical Trial With Livatag® in Primary Liver Cancer 10/22/2013
vasopharm BIOTECH GmbH Reports Endorsement of Phase III Trial Design in Traumatic Brain Injury by European Medicines Agency 10/22/2013
Medivir AB (MVIRb.F) Announces Data From Two Phase 3 Studies With Simeprevir in Hepatitis C Subpopulations – HCV/HIV Co-Infected and Genotype 4 Infected Patients 10/18/2013



//-->